The FDA has approved Auvelity for treating agitation in patients with dementia due to Alzheimer’s disease, Axsome ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

Oral NMDA receptor antagonist gets an expanded indication ...

The Food and Drug Administration (FDA) approved the drug Auvelity this week for the treatment of agitation in adults with ...

While most people are familiar with Alzheimer’s disease, a progressive neurological disorder and the most common cause of dementia, it is often difficult to truly understand the common symptoms and ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed 18 randomized clinical trials that recruited individuals with dementia and ...

Combative and agitated behavior in people with dementia is not rare. Managing this behavior is difficult. Research is limited but cannabis may be of help. The concepts of cannabis use in our society ...

Scientists have found a link between anxiety and dementia risk. Eloisa Ramos/Stocksy Past studies have also found a connection between anxiety and an increased risk for dementia. Now, researchers from ...

This year's winner in NPR's College Podcast Challenge is a letter to a grandparent that grapples with health issues including ...

The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics' Auvelity (dextromethorphan ...

The FDA has approved Auvelity for AD agitation. The combination of dextromethorphan and bupropion is the first oral non-antipsychotic approved for this indication.